文献速递腹部介入US

超声引导下术中肝脏消融——适应证与结局的回顾性分析

Ultrasound-guided intraoperative liver ablation - retrospective review of indications and outcomes.
PubMed 文献 · Clin Radiol · 2024-12-31

该回顾性研究纳入2001年7月至2021年8月接受术中肝脏消融的27例患者共42个肿瘤,主要适应证为同期肝部分切除、术中检出 new 肿瘤及经皮途径不安全;25例可随访患者32个消融肿瘤中技术成功31个(97%),局部肿瘤进展率32%,中位进展时间13.7个月,不良事件率55.5%,80%无需或仅需 minimal 干预。

要点

  • 术中肝脏消融技术成功率高(97%),但局部肿瘤进展率亦较高(32%)。
  • 主要适应证为同期肝部分切除、术中检出 new 肿瘤及经皮消融路径不安全。
  • 不良事件率55.5%,但80%仅需 minimal 或无干预。

核心结论

  • 术中肝脏消融的适应证包括同期肝部分切除、术中检出 new 肿瘤及经皮消融条件欠佳;该技术有效且技术成功率高,但局部肿瘤进展率高,不良事件率相对较高,不过多数病例无需 significant 治疗。

研究设计与样本

  • 回顾性研究,纳入2001年7月至2021年8月接受术中肝脏消融的27例患者(男/女:19/8;平均年龄56±13岁)共42个肿瘤,包括结直肠癌肝转移27个、肝细胞癌14个、卵巢癌转移1个;平均肿瘤直径2.1±1.3 cm(范围0.6-5.6 cm);中位影像随访26.3±25.6个月(范围0.13-161.6个月);采用Kaplan-Meier法计算技术成功、局部肿瘤进展和局部无进展生存;不良事件按SIR指南分类。

关键影像表现/征象

  • 术中肝脏消融的适应证包括同期肝部分切除(9例)、术中检出 new 肿瘤(4例)、缺乏安全经皮穿刺路径(3例)或肝门阻断(1例)。
  • 7例患者由外科医生独立决定行术中消融,并非基于既定标准。
  • 25例可随访患者的32个消融肿瘤中,31个达到技术成功(97%)。
  • 32%的病例检测到局部肿瘤进展,中位时间为13.7个月。
  • 局部无进展生存率在1、2、3、5年分别为82%、60%、51%、51%。

诊断标准与关键数值

  • 技术成功定义为31/32个肿瘤(97%)达到技术成功。
  • 局部肿瘤进展率为32%,中位进展时间13.7个月。
  • 局部无进展生存率:1年82%、2年60%、3年51%、5年51%。
  • 不良事件按SIR指南分类,发生率为55.5%,80%的病例仅需 minimal 或无干预。

临床应用与阅片要点

  • 术中肝脏消融适用于同期肝部分切除、术中检出 new 肿瘤或经皮消融路径不安全等情形。
  • 尽管技术成功率高,仍需关注局部肿瘤进展风险,局部无进展生存率随时间下降。
  • 不良事件较常见,但多数轻微,仅需 minimal 或无干预;严重并发症如肝衰竭虽罕见但可致死。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To define the indications and outcomes of intraoperative ablation of hepatic malignancies.

MATERIALS AND METHODS: This retrospective study comprises 27 patients (male/female: 19/8; mean age: 56 ± 13) undergoing intraoperative ablation (IOA) of liver tumours between July 2001 and August 2021 for 42 tumours, including colorectal liver metastasis (CRLM) (n = 27), hepatocellular carcinoma (HCC)(n = 14), and ovarian cancer metastasis (n = 1). The mean tumour diameter was 2.1 cm ± 1.3 (range, 0.6-5.6 cm). The median imaging follow-up was 26.3 months ± 25.6 (range: 0.13-161.6). Technical success (TS), local tumour progression (LTP), and local progression-free survival (LPFS) were calculated leveraging the Kaplan-Meier method. Adverse events (AE) were categorised according to SIR guidelines.

RESULTS: Indications for IOA include concurrent partial hepatectomy (n = 9), intraoperative detection of a new tumour (n = 4), lack of a safe percutaneous trajectory (n = 3) or clamp of hilum (n = 1). In 7 patients, surgeons made independent decisions for IOA not based on established criteria. Of 32 ablated tumours among 25 patients with available follow-up, TS was achieved for 31 tumours (97%). LTP was detected in 32% of cases at a median of 13.7 months. LPFS at 1,2,3,5 years were 82%, 60%, 51%, 51%. AE rate was 55.5% addressed with minimal or no interventions in 80% of cases. One patient with HCC died of liver failure.

CONCLUSION: The indications for IOA are concurrent partial hepatectomy, intraoperative detection of a new tumour, and suboptimal percutaneous ablation. IOA is effective with high TS. LTP is high. AE rate is relatively high; however, no significant treatment is required in most cases.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Rouhezamin MR, Iqbal SI, Qadan M, et al. Ultrasound-guided intraoperative liver ablation - retrospective review of indications and outcomes. Clin Radiol. 2024. PMID: 39881460. doi:10.1016/j.crad.2024.106793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。